We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neurocognitive Enhancement in Major Depressive Disorder (MDDNET)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00998569
First Posted: October 20, 2009
Last Update Posted: August 31, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Christopher Bowie, Queen's University
  Purpose
The purpose of this study is to examine the effects of neurocognitive enhancement on cognitive abilities and related social and adaptive behaviours in individuals diagnosed with major depressive disorder. Subjects in this study will be randomized to receive Neurocognitive Enhancement Therapy (NET) or to a wait list and then NET . Secondary aims include examining whether the cognitive benefits are potentiated by repeated exposure during in-home practice with complementary exercises. Additionally, the investigators will examine the durability of the effects and their generalization to functional capacity and everyday functional performance after completion of the groups.

Condition Intervention
Major Depressive Disorder Behavioral: Neurocognitive Enhancement Behavioral: Wait List

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Neurocognitive Enhancement in Major Depressive Disorder

Further study details as provided by Christopher Bowie, Queen's University:

Primary Outcome Measures:
  • Performance on paper and pencil assessments of neurocognition after treatment, compared to baseline assessment performance [ Time Frame: 20 weeks ]

Enrollment: 33
Study Start Date: October 2009
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Neurocognitive Enhancement
neurocongnitive enhancement
Behavioral: Neurocognitive Enhancement
Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
Wait List
no intervention
Behavioral: Wait List
Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or Female.
  2. Subjects will be between the ages of 18 and 65, which is the age range with available normative comparison data.

Exclusion Criteria:

  1. Presence of a medical diagnosis that is associated with known cognitive impairments, such as multiple sclerosis, cerebrovascular accident, dementia, or history of traumatic brain injury.
  2. Subjects with a reading level below grade 6, as assessed with the Wide Range Achievement Test - Reading Recognition Subtest, will be excluded because of the likelihood of not understanding task instructions.
  3. Subjects with uncorrectable vision or hearing impairment that would preclude valid assessments or intervention procedures.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00998569


Locations
Canada, Ontario
Queen's University
Kingston, Ontario, Canada, K7L 3N6
Sponsors and Collaborators
Queen's University
Investigators
Principal Investigator: Christopher Bowie, PhD Queen's University
  More Information

Responsible Party: Christopher Bowie, Ph.D., Queen's University
ClinicalTrials.gov Identifier: NCT00998569     History of Changes
Other Study ID Numbers: PSYC-092-09
First Submitted: October 14, 2009
First Posted: October 20, 2009
Last Update Posted: August 31, 2015
Last Verified: August 2015

Additional relevant MeSH terms:
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms